Q-linea AB (SE:QLINEA)
:QLINEA
Want to see SE:QLINEA full AI Analyst Report?
Top Page
Q-linea AB
(QLINEA)
Select Model
Select Model
Rating:41Neutral
Price Target:
kr17.00
▼(-41.38% Downside)
Action:Reiterated
Date:05/16/26
The score is held down primarily by weak financial performance (large ongoing losses and significant cash burn versus a small, declining revenue base) and a clearly bearish technical trend (below key moving averages with very weak momentum). Valuation provides limited support due to a negative P/E and no dividend yield.
Positive Factors
Recurring razor-and-blades revenue model
A razor-and-blades model creates durable recurring revenue from consumables tied to installed instruments. If instrument placements scale, predictable repeat consumable sales can improve gross margin sustainability, cash conversion and long-term revenue visibility independent of one-time instrument transfers.
Negative Factors
Large cash burn and negative operating cash flow
Very high cash burn relative to revenue forces ongoing financing needs and raises risk of dilution or constrained investment. Persistent negative operating cash flow limits ability to scale sales, service installed base, or invest in commercialization over the next several months without external funding or meaningful revenue ramp.
Read all positive and negative factors
Positive Factors
Negative Factors
Recurring razor-and-blades revenue model
A razor-and-blades model creates durable recurring revenue from consumables tied to installed instruments. If instrument placements scale, predictable repeat consumable sales can improve gross margin sustainability, cash conversion and long-term revenue visibility independent of one-time instrument transfers.
Read all positive factors
Q-linea AB (QLINEA) vs. iShares MSCI Sweden ETF (EWD)
Market Cap
kr323.07M
Dividend YieldN/A
Average Volume (3M)13.43K
Price to Earnings (P/E)―
Beta (1Y)2.72
Revenue Growth106.74%
EPS Growth89.96%
CountrySE
Employees97
SectorHealthcare
Sector Strength45
IndustryMedical - Instruments & Supplies
Share Statistics
EPS (TTM)-20.75
Shares Outstanding18,949,081
10 Day Avg. Volume10,725
30 Day Avg. Volume13,430
Financial Highlights & Ratios
PEG Ratio>-0.01
Price to Book (P/B)0.49
Price to Sales (P/S)14.97
P/FCF Ratio-0.98
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-5.51
Revenue Forecast (FY)kr76.80M
Q-linea AB Business Overview & Revenue Model
Company Description
Q-linea AB (publ), founded in 2008 and based in Uppsala, Sweden, specializes in developing diagnostic instruments and associated consumables for infection detection. The company crafts advanced in vitro diagnostic platforms, specifically engineere...
How the Company Makes Money
Q-linea primarily generates revenue through a “razor-and-blades” model common in clinical diagnostics: (1) instrument/system sales or placements of its automated diagnostic platform to laboratories and hospitals, and (2) recurring sales of proprie...
Q-linea AB Financial Statement Overview
Summary
Income Statement
12
Very Negative
Balance Sheet
55
Neutral
Cash Flow
18
Very Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 9.44M | 11.10M | 2.36M | 4.44M | 12.79M | 9.34M |
| Gross Profit | -179.92M | -180.02M | -11.11M | 995.00K | -21.38M | -25.03M |
| EBITDA | -149.69M | -160.54M | -195.40M | -210.99M | -252.69M | -218.48M |
| Net Income | -170.83M | -182.49M | -216.87M | -229.37M | -275.77M | -233.18M |
Balance Sheet | ||||||
| Total Assets | 333.61M | 369.67M | 147.99M | 231.98M | 207.39M | 466.63M |
| Cash, Cash Equivalents and Short-Term Investments | 223.91M | 258.11M | 25.66M | 81.89M | 72.62M | 166.03M |
| Total Debt | 4.15M | 5.84M | 151.21M | 20.56M | 20.93M | 79.00K |
| Total Liabilities | 29.06M | 31.66M | 175.45M | 42.34M | 45.76M | 35.84M |
| Stockholders Equity | 304.55M | 338.00M | -27.46M | 189.64M | 161.63M | 430.79M |
Cash Flow | ||||||
| Free Cash Flow | -152.89M | -169.68M | -187.49M | -236.86M | -268.11M | -267.02M |
| Operating Cash Flow | -143.32M | -162.12M | -182.50M | -228.52M | -250.86M | -255.05M |
| Investing Cash Flow | -9.21M | -7.22M | -5.04M | -7.77M | 315.25M | -23.82M |
| Financing Cash Flow | 308.53M | 402.12M | 131.27M | 245.41M | -6.60M | 283.81M |
Q-linea AB Technical Analysis
Negative
29.00
Price Trends
18.71
Negative
21.31
Negative
24.63
Negative
Market Momentum
-0.08
Positive
41.18
Neutral
4.90
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SE:QLINEA, the sentiment is Negative. The current price of 29 is above the 20-day moving average (MA) of 18.57, above the 50-day MA of 18.71, and above the 200-day MA of 24.63, indicating a bearish trend. The MACD of -0.08 indicates Positive momentum. The RSI at 41.18 is Neutral, neither overbought nor oversold. The STOCH value of 4.90 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for SE:QLINEA.
Q-linea AB Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
54 Neutral | kr491.07M | -1.55 | -35.70% | ― | 175.00% | 81.46% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
51 Neutral | kr121.00M | -1.71 | -72.82% | ― | 55.24% | 70.00% | |
49 Neutral | kr3.24B | -6.82 | -49.96% | ― | -41.17% | -0.30% | |
49 Neutral | kr216.65M | -3.42 | -51.35% | ― | ― | 9.40% | |
48 Neutral | kr31.30M | -0.39 | -186.13% | ― | ― | 57.42% | |
41 Neutral | kr323.07M | -1.92 | -108.15% | ― | 106.74% | 89.96% |
* Healthcare Sector Average
SE:QLINEA
Q-linea AB
17.35
-30.18
-63.49%
SE:VICO
Vicore Pharma Holding AB
11.50
3.85
50.33%
SE:ISOFOL
Isofol Medical AB
0.68
-0.24
-26.04%
SE:BIOVIC.B
Biovica International AB Class B
0.42
-0.26
-38.29%
SE:DOXA
Doxa AB
0.38
-0.06
-13.77%
SE:GUARD
Guard Therapeutics International AB
1.55
-16.20
-91.26%
Q-linea AB Corporate Events
Q-linea Names Annika Blondeau Henriksson Interim CFO and IR Chief
May 29, 2026
Q-linea AB, a Swedish infection diagnostics firm listed on Nasdaq Stockholm, specializes in rapid antibiotic susceptibility testing for severe infections through its flagship automated ASTar platform, which significantly shortens time-to-result an...
Q-linea AGM Approves New Incentive Plan and Expands Capital Flexibility
May 27, 2026
Q-linea AB’s annual general meeting in Uppsala approved the 2025 accounts, decided to carry forward the result without paying a dividend, and granted discharge from liability to the board and CEO. Shareholders also confirmed a seven-member b...
Q-linea Builds Global Momentum on Expanded ASTar Panel and Leaner Cost Base
Apr 30, 2026
Q-linea reported first-quarter 2026 results marked by a 60% rise in consumables revenue to SEK 1.4 million, a narrower operating loss of SEK 35 million, and successful implementation of a restructuring program expected to deliver annual savings of...
Q-linea Calls 2026 AGM, Proposes No Dividend and New Incentive Plan
Apr 27, 2026
Q-linea AB has called its shareholders to an annual general meeting in Uppsala on 27 May 2026, where they will review the 2025 financial year, elect board members and auditors, and address governance matters including remuneration and committee st...
Q-linea’s 2025 Report Highlights Rapid Infection Diagnostics and ASTar Platform
Apr 24, 2026
Q-linea’s 2025 annual report outlines its mission to help preserve the efficacy of antibiotics by providing rapid diagnostic tools that support optimal treatment of infectious diseases. The company emphasizes its strategy of leveraging stron...
Q-linea wins FDA clearance for expanded ASTar sepsis testing menu
Apr 16, 2026
Q-linea has secured U.S. FDA 510(k) clearance for an expanded Gram-negative blood culture testing menu on its ASTar platform, significantly broadening the system’s clinical scope. The updated Version 2 panel now offers 215 bug–drug com...
Q-linea Expands Middle East Presence With ASTar Deployments in Saudi Arabia
Apr 2, 2026
Q-linea has expanded its Middle East footprint by shipping two ASTar instruments to hospitals in Saudi Arabia, where local distributor AMICO will oversee installation and evaluations ahead of anticipated clinical use in 2026. These units build on ...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.